C. B. Granger

CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL

John J.V. McMurray, Jan Östergren, Karl Swedberg et al. · The Lancet · 2003 · 1K citations

Heart Failure, Charm-added Trial, Cardiovascular Disease +6

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

Michael R. MacDonald, Mark C. Petrie, Fumi Varyani et al. · European Heart Journal · 2008 · 698 citations · Full text

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

Jonas Oldgren, Andrzej Budaj, C. B. Granger et al. · European Heart Journal · 2011 · 531 citations · Full text

CHARM INVESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED LEFT-VENTRICULAR EJECTION FRACTION: THE CHARM-PRESERVED TRIAL

Salim Yusuf, Pfeffer, Karl Swedberg et al. · 2003 · 436 citations

Heart Failure, Cardiovascular Disease, Cardiovascular Pharmacology +6

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

Sigrun Halvorsen, Dan Atar, H. Yang et al. · European Heart Journal · 2014 · 364 citations · Full text